Urban legends series: Oral manifestations of HIV infection

Oral Diseases

Volumn 19, Issue 6, 2013, Pages 533-550

  Patton, Ll ^a   Ramirez Amador, V ^b   Anaya Saavedra, G ^b   Nittayananta, W ^c   Carrozzo, M ^d   Ranganathan, K ^e  

^a UNIVERSITY OF NORTH CAROLINA   (United States)

^b UNIVERSIDAD AUTÓNOMA METROPOLITANA   (Mexico)

^c PRINCE OF SONGKLA UNIVERSITY   (Thailand)

^d NEWCASTLE UNIVERSITY   (United Kingdom)

^e RAGAS DENTAL COLLEGE AND HOSPITAL   (India)

Author keywords

AIDS; HIV; Immune reconstitution inflammatory syndrome; Oral candidiasis; Oral hairy leukoplakia; Oral Kaposi's sarcoma; Oral mucosa; Therapy

Indexed keywords

ANIDULAFUNGIN; ANTIRETROVIRUS AGENT; CLOTRIMAZOLE; CRYSTAL VIOLET; FLUCONAZOLE; MICONAZOLE; POSACONAZOLE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ARTICLE; CD4+ T LYMPHOCYTE; CYMBOPOGON CITRATUS; DIAGNOSTIC ACCURACY; HAIRY LEUKOPLAKIA; HEALTH CARE PERSONNEL; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HUMAN PAPILLOMAVIRUS TYPE 11; HUMAN PAPILLOMAVIRUS TYPE 16; HUMAN PAPILLOMAVIRUS TYPE 18; HUMAN PAPILLOMAVIRUS TYPE 6; IMMUNE RECONSTITUTION INFLAMMATORY SYNDROME; LEMON JUICE; MOUTH DISEASE; OROPHARYNX CANDIDIASIS; PRIORITY JOURNAL; THRUSH; VERRUCA VULGARIS; VIRUS LOAD;

AIDS; HIV; IMMUNE RECONSTITUTION INFLAMMATORY SYNDROME; ORAL CANDIDIASIS; ORAL HAIRY LEUKOPLAKIA; ORAL KAPOSI'S SARCOMA; ORAL MUCOSA; THERAPY;

AIDS-RELATED OPPORTUNISTIC INFECTIONS; ALPHAPAPILLOMAVIRUS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CANDIDIASIS, ORAL; HIV INFECTIONS; HUMANS; LEUKOPLAKIA, HAIRY; MOUTH DISEASES; PAPILLOMAVIRUS INFECTIONS;

EID: 84880307723     PISSN: 1354523X     EISSN: 16010825     Source Type: Journal    
DOI: 10.1111/odi.12103     Document Type: Article

References (131)

1. Ablanedo-Terrazas Y, Alvarado-de la Barrera C, Ormsby CE, Reyes-Terán G (2012). Head and neck manifestations of the immune reconstitution syndrome in HIV-infected patients: a cohort study. Otolaryngol Head Neck Surg 147: 52-56.
2. Adamopoulou M, Vairaktaris E, Panis V, Nkenke E, Neukam FW, Yapijakis C (2008). HPV detection rate in saliva may depend on the immune system efficiency. In Vivo 22: 599-602.
3. AIDS Clinical Trials Group (ACTG) (2009). Immune Reconstitution Inflammation Syndrome (IRIS) Case Definitions (Revised 1 October 2009). Available at: http://actgnetwork.org/IRIS_Case_Definitions (accessed June 20, 2012)
4. Amornthatree K, Sriplung H, Mitarnun W, Nittayananta W (2012). Impacts of HIV infection and long-term use of antiretroviral therapy on the prevalence of oral human papilloma virus type 16. J Oral Pathol Med 41: 309-314.
5. Anaya-Saavedra G, Flores-Moreno B, García-Carrancá A, Irigoyen-Camacho E, Guido-Jiménez M, Ramírez-Amador V (2012). J Oral Pathol Med, doi:10.1111/jop.12032 [Epub ahead of print].
6. Aquino-García SI, Rivas MA, Ceballos-Salobreña A, Acosta-Gio AE, Gaitán-Cepeda LA (2008). Short communication: oral lesions in HIV/AIDS patients undergoing HAART including efavirenz. AIDS Res Hum Retroviruses 24: 815-820.
7. Auluck A, Hislop G, Bajdik C, Poh C, Zhang L, Rosin M (2010). Trends in oropharyngeal and oral cavity cancer incidence of human papillomavirus (HPV)-related and HPV-unrelated sites in a multicultural population: the British Columbia experience. Cancer 116: 2635-2644.
8. Baccaglini L, Atkinson JC, Patton LL, Glick M, Ficarra G, Peterson DE (2007). Management of oral lesions in HIV-positive patients. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 103 (Suppl): S50.e1-S50.e23.
9. Beachler DC, Weber KM, Margolick JB et al (2012). Risk factors for oral HPV infection among a high prevalence population of HIV-positive and at-risk HIV-negative adults. Cancer Epidemiol Biomarkers Prev 21: 122-133.
10. Bhayat A, Yengopal V, Rudolph MJ, Nemutandani MS (2008). Predicting HIV in a public dental facility using group I oral lesions. SADJ 63: 538-540, 542-543.
11. Bhayat A, Yengopal V, Rudolph M (2010). Predictive value of group I oral lesions for HIV infection. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 109: 720-723.
12. Blomberg M, Nielsen A, Munk C, Kjaer SK (2011). Trends in head and neck cancer incidence in Denmark, 1978-2007: focus on human papillomavirus associated sites. Int J Cancer 129: 733-741.
13. Bonham S, Meya DB, Bohjanen PR, Boulware DR (2008). Biomarkers of HIV immune reconstitution inflammatory syndrome. Biomark Med 2: 349-361.
14. Briggs A, Kinghorn GR (2010). Nodular herpes simplex virus-1-positive oral lesions as a manifestation of immune reconstitution inflammatory syndrome. Int J STD AIDS 21: 377-378.
15. Cameron JE, Hagensee ME (2008). Oral HPV complications in HIV-infected patients. Curr HIV/AIDS Rep 5: 126-131.
16. Cameron JE, Mercante D, O'Brien M et al (2005). The impact of highly active antiretroviral therapy and immunodeficiency on human papillomavirus infection of the oral cavity of human immunodeficiency virus-seropositive adults. Sex Transm Dis 32: 703-709.
17. Carrozzo M (2011). Urban legends. Oral Dis 17: 753-754.
18. Castillo JJ, Reagan JL (2011). Plasmablastic lymphoma: a systematic review. Sci World J 11: 687-696.
19. Centers for Disease Control (1998). Report of the NIH panel to define principles of therapy of HIV infection and guidelines for the use of antiretroviral agents in HIV-infected adults and adolescents. MMWR 47: 1-82.
20. Centers for Disease Control, National Institutes of Health, and the HIV Medicine Association of the Infectious Diseases Society of America (2009). Guidelines for prevention and treatment of opportunistic infections in HIV-infected adults and adolescents. MMWR 58: 1-207.
21. Centers for Disease Control and Prevention (2006). Revised recommendations for HIV testing of adults, adolescents, and pregnant women in health-care settings. MMWR 55: 1-17.
22. Chaturvedi AK, Engels EA, Anderson WF, Gillison ML (2008). Incidence trends for human papillomavirus-related and -unrelated oral squamous cell carcinomas in the United States. J Clin Oncol 26: 612-619.
23. Chaturvedi AK, Engels EA, Pfeiffer RM et al (2011). Human papillomavirus and rising oropharyngeal cancer incidence in the United States. J Clin Oncol 29: 4294-4301.
24. Chou R, Huffman LH, Fu R, Smits AK, Korthuis PT, US Preventive Services Task Force (2005). Screening for HIV: a review of the evidence for the U.S. Preventive Services Task Force. Ann Intern Med 143: 55-73.
25. Chou R, Selph S, Dana T et al (2012). Screening for HIV: systematic review to update the 2005 U.S. Preventive Services Task Force recommendation. Ann Intern Med 157: 706-718.
26. Collins CD, Cookinham S, Smith J (2011). Management of oropharyngeal candidiasis with localized oral miconazole therapy: efficacy, safety, and patient acceptability. Patient Prefer Adherence 5: 369-374.
27. Coogan MM, Greenspan J, Challacombe SJ (2005). Oral lesions in infection with human immunodeficiency virus. Bull World Health Organ 83: 700-706.
28. Corti M, Solari R, Cangelosi D, De Carolis L, Schtirbu R, Lewi D (2007). Oral cavity lymphoma as secondary AIDS-defining neoplasm in a patient on HAART with immune reconstitution. Rev Soc Bras Med Trop 40: 582-584.
29. Department of Health and Human Services (2011). Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. October 14, 2011; 1-167. Available at: http://www.aidsinfo.nih.gov/ContentFiles/AdultandAdolescentGL.pdf (accessed April 2012).
30. D'Souza G, Fakhry C, Sugar EA et al (2007). Six-month natural history of oral versus cervical human papillomavirus infection. Int J Cancer 121: 143-150.
31. Duggal MS, Abudiak H, Dunn C, Tong HJ, Munyombwe T (2010). Effect of CD4+ lymphocyte count, viral load, and duration of taking anti-retroviral treatment on presence of oral lesions in a sample of South African children with HIV+/AIDS. Eur Arch Paediatr Dent 11: 242-246.
32. EC-Clearinghouseon Oral Problems Related to HIV Infection and WHO Collaborating Centre on Oral Manifestations of the Immunodeficiency Virus (1993). Classification and diagnostic criteria for oral lesions in HIV infection. J Oral Pathol Med 22: 289-291.
33. Fakhry C, D'Souza G, Sugar E et al (2006). Relationship between prevalent oral and cervical human papillomavirus infections in human immunodeficiency virus-positive and -negative women. J Clin Microbiol 44: 4479-4485.
34. Fakhry C, Sugar E, D'Souza G, Gillison M (2010). Two-week versus six-month sampling interval in a short-term natural history study of oral HPV infection in an HIV-positive cohort. PLoS ONE 5: e11918.
35. Feller L, Anagnostopoulos C, Wood NH, Bouckaert M, Raubenheimer EJ, Lemmer J (2008). Human immunodeficiency virus-associated Kaposi sarcoma as an immune reconstitution inflammatory syndrome: a literature review and case report. J Periodontol 79: 362-368.
36. Ferreira S, Noce C, Júnior AS et al (2007). Prevalence of oral manifestations of HIV infection in Rio De Janeiro, Brazil from 1988 to 2004. AIDS Patient Care STDS 21: 724-731.
37. Flint SR, Tappuni A, Leigh J, Schmidt-Westhausen AM, MacPhail L (2006). Markers of immunodeficiency and mechanisms of HAART therapy on oral lesions. Adv Dent Res 19: 146-151.
38. French MA, Price P, Stone SF (2004). Immune restoration disease after antiretroviral therapy. AIDS 18: 1615-1627.
39. Gaitán-Cepeda LA, Ceballos Salobreña A, López Ortega K, Arzate Mora N, Jiménez Soriano Y (2008). Oral lesions and immune reconstitution syndrome in HIV+/AIDS patients receiving highly active antiretroviral therapy. Epidemiological evidence. Med Oral Patol Oral Cir Bucal 13: e85-e93.
40. Gaitán-Cepeda LA, Domínguez-Sánchez A, Pavía-Ruz N et al (2010). Oral lesions in HIV+/AIDS adolescents perinatally infected undergoing HAART. Med Oral Patol Oral Cir Bucal 15: e545-e550.
41. Giuliani M, Lajolo C, Sartorio A et al (2008). Oral lesions in HIV and HCV co-infected individuals in HAART era. J Oral Pathol Med 37: 468-474.
42. Greenspan JS (1997). Sentinels and signposts: the epidemiology and significance of the oral manifestations of HIV disease. Oral Dis 3: S13-S17.
43. Greenspan JS, Barr CE, Sciubba JJ, Winkler JR (1992). Oral manifestations of HIV infection. Definitions, diagnostic criteria, and principles of therapy. The U.S.A. Oral AIDS Collaborative Group. Oral Surg Oral Med Oral Pathol 73: 142-144.
44. Greenspan D, Canchola AJ, MacPhail LA, Cheikh B, Greenspan JS (2001). Effect of highly active antiretroviral therapy on frequency of oral warts. Lancet 357: 1411-1412.
45. Grulich AE, van Leeuwen MT, Falster MO, Vajdic CM (2007). Incidence of cancers in people with HIV/AIDS compared with immunosuppressed transplant recipients: a meta-analysis. Lancet 370: 59-67.
46. Haddow LJ, Easterbrook PJ, Mosam A et al (2009). Defining immune reconstitution inflammatory syndrome: evaluation of expert opinion versus 2 case definitions in a South African cohort. Clin Infect Dis 49: 1424-1432.
47. Hammer SM, Eron JJ Jr, Reiss P et al (2008). Antiretroviral treatment of adult HIV infection: 2008 recommendations of the International AIDS Society-USA panel. JAMA 300: 555-570.
48. Hamza OJ, Matee MI, Simon EN et al (2006). Oral manifestations of HIV infection in children and adults receiving highly active anti-retroviral therapy [HAART] in Dar es Salaam, Tanzania. BMC Oral Health 6: 12.
49. Hamza OJ, Matee MI, Brüggemann RJ et al (2008). Single-dose fluconazole versus standard 2-week therapy for oropharyngeal candidiasis in HIV-infected patients: a randomized, double-blind, double-dummy trial. Clin Infect Dis 47: 1270-1276.
50. Hegedus EJ, Moody J (2010). Clinimetrics corner: the many faces of selection bias. J Man Manip Ther 18: 69-73.
51. Hocking JS, Stein A, Conway EL et al (2011). Head and neck cancer in Australia between 1982 and 2005 show increasing incidence of potentially HPV-associated oropharyngeal cancers. Br J Cancer 104: 886-891.
52. Hulley SB, Cummings SR, Browner WS, Grady DG, Newman TB, eds (2007). Designing cross-sectional and case-control studies. In: Designing clinical research. 3rd edn. Lippincott, Williams & Wilkins: Philadelphia, PA, pp. 109-121.
53. Jensen-Fangel S, Pedersen L, Pedersen C et al (2004). Low mortality in HIV-infected patients starting highly active antiretroviral therapy: a comparison with the general population. AIDS 18: 89-97.
54. Jevtović DJ, Salemović D, Ranin J, Pesić I, Zerjav S, Djurković-Djaković O (2005). The prevalence and risk of immune restoration disease in HIV-infected patients treated with highly active antiretroviral therapy. HIV Med 6: 140-143.
55. Kakabadze T, Rukhadze N, Mshvidobadze K, Lomtadze M, Kandelaki G (2008). Oral lesions in HIV-positive patients in Georgia. Georgian Med News 12: 60-65.
56. Khatibi M, Moshari AA, Jahromi ZM, Ramezankhani A (2011). Prevalence of oral mucosal lesions and related factors in 200 HIV+/AIDS Iranian patients. J Oral Pathol Med 40: 659-664.
57. Kim RH, Yochim JM, Kang MK, Shin KH, Christensen R, Park NH (2008). HIV-1 Tat enhances replicative potential of human oral keratinocytes harboring HPV-16 genome. Int J Oncol 33: 777-782.
58. King MD, Reznik DA, O'Daniels CM, Larsen NM, Osterholt D, Blumberg HM (2002). Human papillomavirus-associated oral warts among human immunodeficiency virus-seropositive patients in the era of highly active antiretroviral therapy: an emerging infection. Clin Infect Dis 34: 641-648.
59. Kreimer AR, Alberg AJ, Daniel R et al (2004). Oral human papillomavirus infection in adults is associated with sexual behavior and HIV serostatus. J Infect Dis 189: 686-698.
60. Leidner RS, Aboulafia DM (2005). Recrudescent Kaposi's sarcoma after initiation of HAART: a manifestation of immune reconstitution syndrome. AIDS Patient Care STDS 19: 635-644.
61. Lilly EA, Cameron JE, Shetty KV et al (2005). Lack of evidence for local immune activity in oral hairy leukoplakia and oral wart lesions. Oral Microbiol Immunol 20: 1541-1562.
62. Llibre JM, Falco V, Tural C et al (2009). The changing face of HIV/AIDS in treated patients. Curr HIV Res 7: 365-377.
63. Lourenço AG, Motta AC, Figueiredo LT, Machado AA, Komesu MC (2011). Oral lesions associated with HIV infection before and during the antiretroviral therapy era in Ribeirão Preto, Brazil. J Oral Sci 53: 379-385.
64. Luxton J, Shepherd P (2001). Human papillomavirus antigens and T-cell recognition. Curr Opin Infect Dis 14: 139-143.
65. Ma SC, Hu J, Zhao J, Speight P (2004). Typing human papilloma virus (HPV) infection in the warts of oral mucosa from HIV-positive patients. Hua Xi Kou Qiang Yi Xue Za Zhi 22: 423-425.
66. Marais DJ, Passmore JA, Denny L, Sampson C, Allan BR, Williamson AL (2008). Cervical and oral human papillomavirus types in HIV-1 positive and negative women with cervical disease in South Africa. J Med Virol 80: 953-959.
67. Mataftsi M, Skoura L, Sakellari D (2011). HIV infection and periodontal diseases: an overview of the post-HAART era. Oral Dis 17: 13-25.
68. Meys R, Gotch FM, Bunker CB (2010). Human papillomavirus in the era of highly active antiretroviral therapy for human immunodeficiency virus: an immune reconstitution-associated disease? Br J Dermatol 162: 6-11.
69. Miziara ID, Weber R (2006). Oral candidiasis and oral hairy leukoplakia as predictors of HAART failure in Brazilian HIV-infected patients. Oral Dis 12: 402-407.
70. Miziara ID, Weber R (2008). Oral lesions as predictors of highly active antiretroviral therapy failure in Brazilian HIV-infected children. J Oral Pathol Med 37: 99-106.
71. Miziara ID, Filho BC, Weber R (2006). Oral lesions in Brazilian HIV-infected children undergoing HAART. Int J Pediatr Otorhinolaryngol 70: 1089-1096.
72. Moura MD, Guimarães TR, Fonseca LM, de Almeida Pordeus I, Mesquita RA (2007). A random clinical trial study to assess the efficiency of topical applications of podophyllin resin (25%) versus podophyllin resin (25%) together with acyclovir cream (5%) in the treatment of oral hairy leukoplakia. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 103: 64-71.
73. Moura MD, Haddad JP, Senna MI, Ferreira e Ferreira E, Mesquita RA (2010). A new topical treatment protocol for oral hairy leukoplakia. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 110: 611-617.
74. Nabbanja J, Gitta S, Peterson S, Rwenyonyi CM (2013). Orofacial manifestations in HIV positive children attending Mildmay Clinic in Uganda. Odontology 101: 116-120.
75. Nairy HM, Charyulu NR, Shetty VA, Prabhakara P (2011). A pseudo-randomized clinical trial of in situ gels of fluconazole for the treatment of oropharyngeal candidiasis. Trials 2: 9.
76. Nittayananta W, Talungchit S, Jaruratanasirikul S et al (2010a). Effects of long-term use of HAART on oral health status of HIV-infected subjects. J Oral Pathol Med 39: 397-406.
77. Nittayananta W, Chanowanna N, Winn T (2010b). Mode of HIV transmission associated with risk of oral lesions in HIV-infected subjects in Thailand. J Oral Pathol Med 39: 195-200.
78. Nokta M (2008). Oral manifestations associated with HIV infection. Curr HIV/AIDS Rep 5: 5-12.
79. de Nunes MG, Azevedo-e-Silva M, Gonçalves CP, Trope BM, Oliveira LDOH, Ramos-e-Silva M (2008). Human papillomavirus detection and typification in cutaneous and mucosal lesions of HIV-seropositive patients. Int J STD AIDS 19: 611-616.
80. O'Brien PM, Saveria Campo M (2002). Evasion of host immunity directed by papillomavirus-encoded proteins. Virus Res 88: 103-117.
81. Ortega KL, Ceballos-Salobreña A, Gaitán-Cepeda LA, Magalhães MG (2008). Oral manifestations after immune reconstitution in HIV patients on HAART. Int J STD AIDS 19: 305-308.
82. Ortega KL, Vale DA, Magalhães MH (2009). Impact of PI and NNRTI HAART-based therapy on oral lesions of Brazilian HIV-infected patients. J Oral Pathol Med 38: 489-494.
83. Palefsky J (2006). Biology of HPV in HIV infection. Adv Dent Res 19: 99-105.
84. Palefsky JM, Rubin M (2009). The epidemiology of anal human papillomavirus and related neoplasia. Obstet Gynecol Clin North Am 36: 187-200.
85. Palfreeman A, Fisher M, Ong E et al (2009). Testing for HIV: concise guideline. Clin Med 9: 471-476.
86. Paltiel AD, Weinstein MC, Kimmel AD et al (2005). Expanded screening for HIV in the United States-an analysis of cost-effectiveness. N Engl J Med 352: 586-595.
87. Papagatsia Z, Jones J, Morgan P, Tappuni AR (2009). Oral Kaposi sarcoma: a case of immune reconstitution inflammatory syndrome. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 108: 70-75.
88. Parisi SG, Cruciani M, Scaggiante R et al (2011). Anal and oral human papillomavirus (HPV) infection in HIV-infected subjects in northern Italy: a longitudinal cohort study among men who have sex with men. BMC Infect Dis 11: 150.
89. Patton LL, McKaig RG, Eron JJ Jr, Lawrence HP, Strauss RP (1999). Oral hairy leukoplakia and oral candidiasis as predictors of HIV viral load. AIDS 13: 2174-2176.
90. Patton LL, McKaig R, Strauss R, Rogers D, Eron JJ Jr (2000). Changing prevalence of oral manifestations of human immune-deficiency virus in the era of protease inhibitor therapy. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 89: 299-304.
91. Pienaar ED, Young T, Holmes H (2010). Interventions for the prevention and management of oropharyngeal candidiasis associated with HIV infection in adults and children. Cochrane Database Syst Rev 11: CD003940.
92. Pinheiro A, Marcenes W, Zakrzewska JM, Robinson PG (2004). Dental and oral lesions in HIV infected patients: a study in Brazil. Int Dent J 54: 131-137.
93. Piperi E, Omlie J, Koutlas IG, Pambuccian S (2010). Oral hairy leukoplakia in HIV-negative patients: report of 10 cases. Int J Surg Pathol 18: 177-183.
94. Pomarico L, Cerqueira DF, de Araujo Soares RM et al (2009). Associations among the use of highly active antiretroviral therapy, oral candidiasis, oral Candida species and salivary immunoglobulin A in HIV-infected children. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 108: 203-210.
95. Ramírez-Amador V, Ponce-de-León S, Anaya-Saavedra G, Crabtree Ramírez B, Sierra-Madero J (2007). Oral lesions as clinical markers of highly active antiretroviral therapy failure: a nested case-control study in Mexico City. Clin Infect Dis 45: 925-932.
96. Ramírez-Amador VA, Espinosa E, González-Ramírez I, Anaya-Saavedra G, Ormsby CE, Reyes-Terán G (2009). Identification of oral candidiasis, hairy leukoplakia and recurrent oral ulcers as distinct cases of immune reconstitution inflammatory syndrome. Int J STD AIDS 20: 259-261.
97. Ramos-Gomez FJ, Flaitz C, Catapano P, Murray P, Milnes AR, Dorenbaum A (1999). Classification, diagnostic criteria, and treatment recommendations for orofacial manifestations in HIV-infected pediatric patients. Collaborative Workgroup on Oral Manifestations of Pediatric HIV Infection. J Clin Pediatr Dent 23: 85-96.
98. Ranganathan K, Reddy BVR, Kumaraswamy N, Solomon S, Viswanathan R, Johnson NW (2000). Oral lesions and conditions associated with Human Immunodeficiency Virus infection in 300 south Indian patients. Oral Dis 6: 152-157.
99. Richards D (2009). Grading- levels of evidence. Evid Based Dent 10: 24-25.
100. Richter KL, van Rensburg EJ, van Heerden WF, Boy SC (2008). Human papilloma virus types in the oral and cervical mucosa of HIV-positive South African women prior to antiretroviral therapy. J Oral Pathol Med 37: 555-559.
101. Robinson PG, Challacombe SJ, Sheiham A (1998). Oral examination: a screening tool for HIV infection? Sex Transm Infect 74: 345-348.
102. Rwenyonyi CM, Kutesa A, Muwazi L, Okullo I, Kasangaki A, Kekitinwa A (2011). Oral manifestations in HIV/AIDS-infected children. Eur J Dent 5: 291-298.
103. Ryerson AB, Peters ES, Coughlin SS et al (2008). Burden of potentially human papillomavirus-associated cancers of the oropharynx and oral cavity in the US, 1998-2003. Cancer 113: 2901-2909.
104. Sales-Peres SH, Mapengo MA, de Moura-Grec PG, Marsicano JA, de Sales-Peres AC, Sales-Peres A (2012). Oral manifestations in HIV+ children in Mozambique. Cien Saude Colet 17: 55-60.
105. dos Santos Pinheiro R, França TT, Ribeiro CM, Leão JC, de Souza IP, Castro GF (2009). Oral manifestations in human immunodeficiency virus infected children in highly active antiretroviral therapy era. J Oral Pathol Med 38: 613-622.
106. Schache AG, Liloglou T, Risk JM et al (2011). Evaluation of human papilloma virus diagnostic testing in oropharyngeal squamous cell carcinoma: sensitivity, specificity and prognostic discrimination. Clin Cancer Res 17: 6262-6271.
107. Schiødt M, Bakilana PB, Hiza JF et al (1990). Oral candidiasis and hairy leukoplakia correlate with HIV infection in Tanzania. Oral Surg Oral Med Oral Pathol 69: 591-596.
108. Schmidt-Westhausen AM, Priepke F, Bergmann FJ, Reichart PA (2000). Decline in the rate of oral opportunistic infections following introduction of highly active antiretroviral therapy. J Oral Pathol Med 29: 336-341.
109. Shangase L, Feller L, Blignaut E (2004). Necrotising ulcerative gingivitis/periodontitis as indicators of HIV-infection. SADJ 59: 105-108.
110. Shelburne SA, Montes M, Hamill RJ (2006). Immune reconstitution inflammatory syndrome: more answers, more questions. J Antimicrob Chemother 57: 167-170.
111. Shiboski CH, Patton LL, Webster-Cyriaque JY et al (2009). The oral HIV/AIDS research alliance: updated case definitions of oral disease endpoints. J Oral Pathol Med 38: 481-488.
112. da Silva CA, Dourado I, Dahia SR, Harzheim E, Rutherford GW (2008). Oral manifestations of HIV infection in patients receiving highly active antiretroviral therapy (HAART) in Bahia, Brazil. J Public Health Dent 68: 178-181.
113. Skiest DJ, Vazquez JA, Anstead GM et al (2007). Posaconazole for the treatment of azole-refractory oropharyngeal and esophageal candidiasis in subjects with HIV infection. Clin Infect Dis 44: 607-614.
114. Steinau M, Reddy D, Sumbry A et al (2012). Oral sampling and human papillomavirus genotyping in HIV-infected patients. J Oral Pathol Med 41: 288-291.
115. Sun HY, Chen MY, Hsiao CF, Hsieh SM, Hung CC, Chang SC (2006). Endemic fungal infections caused by Cryptococcus neoformans and Penicillium marneffei in patients infected with human immunodeficiency virus and treated with highly active anti-retroviral therapy. Clin Microbiol Infect 12: 381-388.
116. Syrjänen S (2011). Human papillomavirus infection and its association with HIV. Adv Dent Res 23: 84-89.
117. Tamí-Maury IM, Willig JH, Jolly PE et al (2011). Prevalence, incidence, and recurrence of oral lesions among HIV-infected patients on HAART in Alabama: a two-year longitudinal study. South Med J 104: 561-566.
118. Thompson MA, Aberg JA, Cahn P et al (2010). 2010 recommendations of the International AIDS Society-USA panel. JAMA 304: 321-333.
119. Tsang CS, Samaranayake LP (2010). Immune reconstitution inflammatory syndrome after highly active antiretroviral therapy: a review. Oral Dis 16: 248-256.
120. Umadevi M, Adeyemi O, Patel M, Reichart PA, Robinson PG (2006). (B2) Periodontal diseases and other bacterial infections. Adv Dent Res 19: 139-145.
121. Umadevi KM, Ranganathan K, Pavithra S et al (2007). Oral lesions among persons with HIV disease with and without highly active antiretroviral therapy in southern India. J Oral Pathol Med 36: 136-141.
122. United States Preventive Services Task Force (2005). Screening for HIV. Available at: http://www.uspreventiveservicestaskforce.org/uspstf/uspshivi.htm (accessed February 4, 2013).
123. Vazquez JA (2007). Posaconazole for the management of mucosal candidiasis. Future Microbiol 2: 245-256.
124. Vazquez JA (2010). Optimal management of oropharyngeal and esophageal candidiasis in patients living with HIV infection. HIV AIDS 2: 89-101.
125. Vazquez JA, Skiest DJ, Nieto L et al (2006). A multicenter randomized trial evaluating posaconazole versus fluconazole for the treatment of oropharyngeal candidiasis in subjects with HIV/AIDS. Clin Infect Dis 42: 1179-1186.
126. Vazquez JA, Schranz JA, Clark K, Goldstein BP, Reboli A, Fichtenbaum C (2008). A phase 2, open-label study of the safety and efficacy of intravenous anidulafungin as a treatment for azole-refractory mucosal candidiasis. J Acquir Immune Defic Syndr 48: 304-309.
127. Vazquez JA, Patton LL, Epstein JB et al (2010). Randomized, comparative, double-blind, double-dummy, multicenter trial of miconazole buccal tablet and clotrimazole troches for the treatment of oropharyngeal candidiasis: study of miconazole Lauriad® efficacy and safety (SMiLES). HIV Clin Trials 11: 186-196.
128. World Health Organization (2007). WHO Case Definitions of HIV for Surveillance and Revised Clinical Staging and Immunological Classification of HIV-Related Disease in Adults and Children. Geneva, Switzerland. Available at: http://www.who.int/hiv/pub/guidelines/HIVstaging150307.pdf (accessed June 9, 2012).
129. Wright SC, Maree JE, Sibanyoni M (2009). Treatment of oral thrush in HIV/AIDS patients with lemon juice and lemon grass (Cymbopogon citratus) and gentian violet. Phytomedicine 16: 118-124.
130. Wu G, Zaman MH (2012). Low-cost tools for diagnosing and monitoring HIV infection in low-resource settings. Bull World Health Organ 90: 914-920.
131. Yengopal V, Bhayat A, Coogan M (2011). Pediatric oral HIV research in the developing world. Adv Dent Res 23: 61-66.